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Abstract The bacterial cytolethal distending toxin (CDT)
triggers a G2/M cell cycle arrest in eukaryotic cells by inhibiting
the CDC25C phosphatase-dependent CDK1 dephosphorylation
and activation. We report that upon CDT treatment CDC25C is
fully sequestered in the cytoplasmic compartment, an effect that
is reminiscent of DNA damage-dependent checkpoint activation.
We show that the checkpoint kinase CHK2, an upstream
regulator of CDC25C, is phosphorylated and activated after
CDT treatment. In contrast to what is observed with other DNA
damaging agents, we demonstrate that the activation of CHK2
can only take place during S-phase. Use of wortmannin and
caffeine suggests that this effect is not dependent on ATM but
rather on another as yet unidentified PI3 kinase family member.
These results confirm that the CDT is therefore responsible for
specific genomic injuries that block cell proliferation by
activating a cell cycle checkpoint. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Bacterial cytotoxins are proteins whose ability to interfere
with eukaryotic cell cycle opens new areas in our understand-
ing of cellular proliferation. A family of cytolethal distending
toxins (CDT) found in various bacterial species including Es-
cherichia coli, Shigella dysenteriae and Campylobacter jejuni
inhibit proliferation in a vast majority of vertebrate cell lines
[1]. In HeLa cells, exposure to CDT induces a cell cycle block
at the G2/M transition which results in the maintenance of
CDK1, a key regulator of entry in mitosis, in a tyrosine 15
phosphorylated inactive form [2,3]. The CDC25 phosphatase
is able to reverse this state to a fully active CDK1/cyclin B
complex both in vitro and in vivo implying that phosphory-
lation on tyrosine 15 is responsible for the maintenance of an
inactive CDK1 [3,4]. Although genomic injuries were not de-
tected by comet assay upon CDT treatment of HeLa cells [3],
this situation was reminiscent of a signalling cascade which
activates a G2/M checkpoint following DNA damage [5]. In
agreement with this hypothesis, it has recently been shown
that DNase I homologous residues are present in cdtB and
are critical for CDT-induced cell cycle arrest [6,7].
In eukaryotes, cell cycle checkpoints help to ensure the
orderly progression and completion of critical events such as
DNA replication and chromosome segregation [8]. By acting
at di¡erent stages in the cell cycle, checkpoints delay G1/S or
G2/M transitions or inhibit DNA synthesis depending on the
type of injury [9]. Defects in the checkpoint pathway often
result in enhanced sensitivity to damaging agents and could
increase genomic instability. Two members of the phosphatid-
yl inositol kinase (PIK)-related kinase family are important
components of this DNA damage response pathway ATM,
which is mutated in ataxia telangectasia (AT) syndrome and
a related protein called ATR (for ATM and Rad3-related).
Cells from AT individuals display an increased rate of chro-
mosomal recombination and are defective in ionizing radia-
tion (IR)-inducible G1/S, S-phase and G2/M checkpoints.
Once these PIK-related kinases have been activated, the
next stage is activation/phosphorylation of downstream tar-
gets including tumor suppressor gene p53 [10^12], and check-
point proteins 1 and 2 (CHK1 and CHK2). CHK2 is phos-
phorylated in an ATM-dependent manner in response to IRs
which induce double-strand breaks and in an ATM-independ-
ent and possibly ATR-dependent manner in response to UV
light and stalled replication [13^15]. In the case of CHK1 the
available evidence suggests that in the case of UV irradiation
its response to DNA damage is ATR-dependent [16,17].
Human CHK2 and CHK1 phosphorylate CDC25C on ser-
ine 216 [13,18^20] thus creating a binding site for 14.3.3 pro-
teins that is responsible for the cytoplasmic sequestration of
CDC25C and the subsequent impairment of nuclear CDK1
dephosphorylation [21]. Other identi¢ed substrates of CHK2
are the tumor suppressor protein p53 [22^24] and BRCA1
[25].
In this study, we have investigated the involvement of
CHK2 in the cell cycle checkpoint response to CDT. We
demonstrate that CHK2 is activated after CDT exposure dur-
ing the S-phase. We also show that ca¡eine but not wortman-
nin is able to revert the CDT-dependent CHK2 activation.
The CDT toxin is therefore able to target the G2/M DNA
cell cycle checkpoint machinery through a mechanism that
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comprises CHK2 activation by an ATM-independent path-
way.
2. Materials and methods
2.1. Cell culture and transfection
HeLa cells, obtained from the American Type Culture Collection,
were cultured in Dulbecco’s modi¢ed Eagle’s medium supplemented
with 10% heat-inactivated fetal calf serum (Eurobio), 2 mM L-gluta-
mine, penicillin (100 U/ml) and streptomycin (100 Wg/ml) in a humidi-
¢ed atmosphere containing 5% CO2 at 37‡C.
2.2. CDT, wortmannin and ca¡eine treatment
CDT was produced from E. coli DH5-K hosting recombinant plas-
mid pDS7-96, which contains the three open reading frames (cdtA,
cdtB and cdtC) necessary to encode CDT activity. The toxic prepara-
tion consisted in the sterile supernatant of a 24 h trypticase soy broth
aerated culture of this recombinant strain as previously described [2].
The toxic activity (CD100) was de¢ned as the lower cytopathic dose
that caused 100% of enlarged cells after 72 h of incubation and where
more than 90% of the exposed cells are irreversibly blocked at stage
G2/M after 24 h. Treatment with ca¡eine (2 mM) and wortmannin
(20 WM) was started 1 h prior to CDT exposure. The cells were then
washed and further treated with ca¡eine or wortmannin during 16 h
before harvesting and biochemical analysis.
2.3. Immuno£uorescence
Cells grown on glass coverslips were recovered, washed once with
PBS, ¢xed in 3.7% formaldehyde in PBS at 4‡C for 40 min then
washed three times with PBS. Cells were then permeabilized with
0.25% Triton X-100 in PBS for 5 min at room temperature and
with a further incubation in 100% cold methanol for 10 min at
320‡C. Fixed and permeabilized cells were then saturated with 1%
BSA in PBS for 15 min at room temperature. The cells were then
incubated for 1 h at 37‡C with polyclonal anti-CDC25C antibody
(C20; Santa Cruz) diluted 1/250 in PBS/BSA 1%. After three washes
with PBS/BSA 1%, the cells were incubated with Alexa 594-conju-
gated goat anti-rabbit antibodies (Molecular Probes) diluted 1/500
in PBS/BSA 1% for 45 min at room temperature, washed in PBS/
BSA 1% and ¢nally incubated with Hoechst 1 Wg/ml for 10 min at
room temperature. Coverslips were washed with PBS and mounted in
Mowiol. Microscopic examinations were performed under a Leica
photomicroscope.
2.4. Immunoblotting
Cells grown on 100 mm petri dishes were harvested by trypsiniza-
tion and centrifuged at 200Ug for 10 min. Cells were then lysed in
20 mM Tris^HCl bu¡er (pH 8.0) containing 250 mM NaCl, 0.5%
Triton X-100, 10 mM NaF, 1 mM Na3VO4, aprotinin (2 Wg/ml),
leupeptin (2 Wg/ml) and 1 mM phenylmethylsulfonyl £uoride
(PMSF) for 15 min at 4‡C. The cell lysates were centrifuged for
10 min at 14 000 rpm. After centrifugation, proteins (10 Wg) were
separated by electrophoresis on 7.5% sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis (SDS^PAGE) and transferred to nitro-
cellulose membranes using a semi-dry transfer apparatus. The mem-
branes were then saturated with non-fat milk (5%) in TBST [26] for
30 min at room temperature then incubated with anti-CHK2 (gift
from Elledge) diluted 1/1000 in TBST for 1 h. After three washes
with TBST, the membranes were incubated with horseradish peroxi-
dase-conjugated secondary antibody (Biolabs) diluted 1/2500 in TBST
for 30 min at room temperature, washed ¢ve times in TBST and
¢nally detected by enhanced chemiluminescence.
2.5. Immunoprecipitation and kinase assay
Cell extracts were prepared as above described. 1 mg of protein was
¢rst pre-cleared by incubation with protein A-Sepharose beads for
45 min at 4‡C. Cell extracts were centrifuged at 14 000 rpm for
10 min and the supernatant was then incubated with anti-CHK2
(1 Wl) for 2 h at 4‡C. Protein A-Sepharose beads were added for 1 h
at 4‡C and then the immunoprecipitated beads were washed four
times with 20 mM Tris^HCl (pH 8.0), 250 mM NaCl, 0.5% Triton
X-100, 10 mM NaF, 1 mM Na3VO4, aprotinin (2 Wg/ml), leupeptin
(2 Wg/ml) and 1 mM PMSF. The CHK2 immunoprecipitates were
then washed three times with 50 mM HEPES (pH 8.0), 10 mM
MgCl2, 2.5 mM EGTA, 1 mM DTT, 1 mM NaF, 0.1 mM Na3VO4
and 0.1 mM PMSF. The kinase assay was performed in 50 mM
HEPES (pH 8.0), 10 mM MgCl2, 2.5 mM EGTA, 1 mM DTT,
1 mM NaF, 0.1 mM Na3VO4, 0.1 mM PMSF, 20 WM adenosine
triphosphate (ATP), and 5 WCi [Q-32P]ATP for 30 min at 30‡C in a
30 Wl reaction volume. Proteins were then separated by SDS^PAGE
and visualized by Coomassie blue staining and autoradiography.
2.6. Flow cytometry
Cell cycle distribution was assessed essentially as described previ-
ously [3] using a FACScalibur £ow cytometer (Becton Dickinson).
Collection and analysis of the cell cycle were performed using the
CellQuest and the ModFit software (Becton Dickinson).
3. Results
3.1. E¡ects of CDT on CDC25C phosphatase intracellular
localization
We ¢rst examined the intracellular localization of CDC25C
in HeLa cells treated or not for 24 h with CDT. As shown in
Fig. 1A, while untreated cells displayed cytoplasmic or nu-
clear localization in agreement with previous publications
[21], CDC25C was fully relocated in the cytoplasm of cells
treated with CDT (Fig. 1B). This is a typical feature of the
G2/M checkpoint activation, where the phosphorylation of
CDC25C leads to its binding to 14.3.3 proteins and to its
cytoplasmic accumulation and functional inactivation. This
observation as well as our recent ¢ndings that CDC25C over-
expression bypassed G2/M arrest in CDT-treated cells [4], led
us to examine the involvement of an upstream regulator of
CDC25C, the checkpoint kinase CHK2, in that regulation.
3.2. CHK2 is activated in CDT-treated HeLa cells
In order to investigate the e¡ects of CDT on CHK2, HeLa
cells were treated for 24 h with 1 CD100 CDT or for 1 h with
30 WM etoposide as positive control, then washed twice and
harvested 23 h later. Protein extracts were prepared and sub-
jected to Western blot analysis using CHK2 antibodies. It has
been reported for genotoxic treatment or replication block
that the activation of checkpoint 2 (CHK2) protein kinase
leads to a reduction of its electrophoretic mobility [13,27].
As shown in Fig. 2A a slower mobility form of CHK2 was
also detected after CDT or etoposide treatment. Similar re-
sults were also observed when normal diploid ¢broblasts
IMR90 were treated with CDT (data not shown). Exposure
of immunoprecipitated CHK2 to lambda phosphatase led to
disappearance of the slower electrophoretic mobility form in-
dicating that CHK2 is indeed phosphorylated in CDT-treated
HeLa cells (not shown).
It has been demonstrated that in response to gamma irra-
diation CHK2 phosphorylation correlated with an increase in
its protein kinase activity [13,14]. CHK2 was therefore immu-
noprecipitated from treated and untreated cells and subjected
to a kinase assay. As shown in Fig. 2B, CHK2 kinase activity
was at least 3-fold higher in CDT-treated cells as compared to
untreated cells strengthening the fact that CHK2 is activated
in response to CDT.
In order to investigate the relation between CDT treatment
and activation of CHK2, a kinetic analysis of its phosphory-
lation was also performed by monitoring CHK2 change in
electrophoretic mobility (Fig. 2C). Surprisingly in asynchro-
nous HeLa cells exposed to CDT, CHK2 phosphorylation
was barely detectable after 8 h and required about 24 h to
be at a maximum. This result contrasts with data obtained
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after gamma irradiation of HeLa cells where CHK2 was fully
phosphorylated in less than 30 min [13].
3.3. CHK2 is rapidly phosphorylated in S-phase but not in
G2-phase in HeLa cells
The slow kinetics of accumulation of the CHK2 phosphor-
ylated form together with the fact that passage of the cells
through S-phase has been shown to be required for CDT
activity [3], prompted us to investigate whether they should
proceed to a speci¢c stage of the cell cycle in order to allow
CHK2 activation by CDT. To address that issue, HeLa cells
were synchronized at the G1/S boundary using a double thy-
midine block then released and CDT was subsequently added
at di¡erent stages of the cell cycle. Progression in the cell cycle
was monitored in these experiments by £ow cytometry in
treated and untreated cells. In the case of CDT added just
after release from thymidine block (i.e. at G1/S), the CHK2
phosphorylation was completed after 8 h and remains at this
level up to 24 h (Fig. 3A). This phosphorylation of CHK2
fully paralleled the accumulation of the cells in G2. When the
cells were treated by CDT 4 h after release from G1/S (i.e. in
S-phase), complete CHK2 phosphorylation was achieved in
about 4 h (Fig. 3B) and was also coincident with G2 accumu-
lation. In contrast, when the cells were treated by CDT 8 h
after release from thymidine block, i.e. when they were al-
ready mostly in G2, at least a 16 h delay was necessary to
observe 50% of CHK2 phosphorylated form and nearly 24 h
for a complete phosphorylation (Fig. 3C). That delay was also
necessary to observe the accumulation of the cells with a G2
DNA content. This set of results indicates that in contrast to
what has been reported with IRs, progression of the cells
Fig. 1. Intracellular localization of CDC25C in CDT-treated cells. Exponentially growing HeLa cells were treated (B) or not (A) for 24 h with
CDT. After 24 h the cells were ¢xed and processed for immuno£uorescence detection of CDC25C using C20 antibodies.
Fig. 2. Phosphorylation and activation of CHK2 in HeLa cells ex-
posed to CDT. A: Asynchronous HeLa cells were treated or not
with CDT or etoposide. For CDT the cells were treated for 24 h
then harvested. For etoposide, cells were treated for 1 h then
washed twice and collected 23 h later. Proteins were fractionated on
SDS^PAGE and CHK2 was detected by Western blotting using
anti-CHK2 antibodies. B: Immunoprecipitation of CHK2 from un-
treated, CDT-treated or etoposide-treated cells was performed in the
presence or in the absence of immunizing peptide (pept.) then incu-
bated with [Q-32P]ATP for 30 min at 30‡C then subjected to SDS^
PAGE and autoradiography. C: Asynchronous HeLa cells were
treated with CDT then collected at various times and analyzed as in
A.
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through S-phase is necessary to achieve the activation of
CHK2 after treatment by the CDT toxin.
3.4. ATM independence of CHK2 activation in cells exposed to
CDT
As we have already shown previously that ca¡eine is able to
revert CDT-dependent cell cycle arrest in G2 [3] and given the
fact that ca¡eine appears to inhibits ATM and ATR, we ex-
amined whether these PI3-related kinases were involved in
CDT-dependent CHK2 activation. To examine that question,
asynchronous HeLa cells were incubated with 2 mM ca¡eine
or 20 WM wortmannin prior to CDT treatment. After 16 h,
cells were lysed and protein extracts were analyzed by Western
blot with anti-CHK2 antibody. As shown in Fig. 4, ca¡eine
led to an important decrease in the phosphorylated CHK2
form. In contrast, wortmannin had little or no e¡ect on the
phosphorylation status of CHK2.
4. Discussion
Previous studies have shown that the checkpoint 2 protein
kinase (CHK2) is phosphorylated/activated in response to
various stimuli as replication blocks by hydroxyurea or gen-
otoxic treatment with gamma irradiation or agent causing
DNA breaks such as etoposide. Here, we report that CHK2
is activated when HeLa cells are treated with E. coli CDT.
This activation was in the ¢rst place surprising because no
DNA damages were detected using a comet assay in our pre-
vious work [3]. However, two recent publications strongly
suggest that CDT toxins are able to target directly the
DNA of the host cells through an intrinsic DNase I-like ac-
tivity [6,7]. Our results presented here demonstrate that in
response to DNA damages that are either beyond the detec-
tion level or not detectable by comet assay, CDT activates a
CHK2-dependent pathway that leads to cell cycle arrest in
G2. However, there are a number of signi¢cant di¡erences
with the CHK2 activation that has been reported after other
genomic injuries.
Studies in ¢ssion yeast Schizosaccharomyces pombe have
shown that CHK2/cds1 could be activated only in S-phase
following DNA damage [28]. When cds1 vertebrate homolo-
gous CHK2 was identi¢ed, similar studies could not have
been reproduced suggesting that the activation of CHK2 in
animals was not cell cycle-dependent. In particular Elledge’s
group has studied CHK2 activation following gamma irradi-
ation and has found that it occurs in less than 2 h independ-
ently of cell cycle phase [13]. In this work, we took advantage
of the fact that CDT could not trigger an immediate G2/M
block when cells were exposed in G2-phase [2,3]. When HeLa
Fig. 3. Cell cycle regulated activation of CHK2 following exposure to CDT. HeLa cells were synchronized by a double thymidine block as de-
scribed [3]. Cells were then released from G1/S block by double washing with PBS. A: Cells were treated immediately with CDT. B: Cells were
released for 4 h before exposure to CDT. C: Cells were released for 8 h before exposure to CDT. A, B and C: Cells were harvested at the in-
dicated times after treatment by CDT and subjected to Western blot analysis of CHK2 phosphorylation (top panel) and to cell cycle distribu-
tion analysis by £ow cytometry after propidium iodide staining. Both untreated and CDT-treated cells were analyzed by £ow cytometry. Note
that in all panels the experiment started when CDT was added, that is to say immediately after thymidine block release (A), 4 h later (B) and
8 h later (C).
Fig. 4. ATM independence of CDT-induced CHK2 phosphoryla-
tion. Asynchronous HeLa cells were pre-treated with ca¡eine or
wortmannin for 1 h before addition of CDT. Cells were washed
and inhibitors were added again. Cells were collected after 16 h and
proteins were fractionated on SDS^PAGE and visualized by immu-
noblotting with anti-CHK2 antibodies. CHK2 and its phosphorylat-
ed form are indicated with arrows.
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cells were synchronized by double thymidine block, we found
that exposure to CDT in the middle of S-phase leads to
CHK2 phosphorylation in less than 4 h which was compatible
with a speci¢c time window in S-phase.
The discrepancy between timing of CHK2 activation fol-
lowing gamma irradiation and CDT treatment could be ex-
plained by toxin processing requirements. Each of the steps of
this process could be unavailable during a speci¢c stage of the
cell cycle and therefore could delay signalling. In contrast
DNA breakage provoked by radiations is immediately sen-
sored and therefore not subjected to cell cycle regulation.
Alternately, as proposed by others [6] the DNase I-like activ-
ity of the cdtB subunit may only be active in S-phase because
it is speci¢cally directed against single-strand DNA or it is
dependent on co-factors that are only present in S-phase.
In the aim to identify the signalling cascade involved in the
cellular response to CDT, we investigated if we could inhibit
CHK2 activation by pre-treating HeLa cells with ca¡eine or
wortmannin. Ca¡eine is well known to overcome G2 check-
point control related to DNA damage or replication blocks
[29]. Recently it has been shown that ca¡eine is able to di-
rectly inhibit ATM and ATR in vitro with an IC50 of 0.2 mM
[30]. We have found in this work that ca¡eine was able to
interfere with CDT-dependent CHK2 activation and as re-
ported in a previous study, this e¡ect was able to prevent
CDT-dependent cell cycle arrest [3]. In contrast, wortmannin
had no e¡ects on CHK2 phosphorylation at a concentration
that is known to inhibit ATM but not ATR [31]. Altogether,
these data suggest that an ATM-related kinase, as a ca¡eine
sensitive and wortmannin insensitive protein (at the concen-
tration used in this study) is an upstream regulator of CHK2
in CDT-treated cells. Whether this kinase is ATR remains to
be fully demonstrated. In agreement with this proposal, ATR
has been involved in replication checkpoint and we have
shown in this paper that CHK2 activation takes place during
S-phase. One can reasonably conclude that the bacterial toxin
CDT can activate CHK2, a major key regulator of G2/M
checkpoint, probably by creating DNA damages in S-phase
that are signalled through an ATM-related kinase-dependent
pathway.
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